Open Access

Change in tartrate‑resistant acid phosphatase isoform 5b levels, a marker of bone metabolism, in patients with chronic hepatitis B treated with tenofovir alafenamide

  • Authors:
    • Takuma Okamura
    • Tatsuki Ichikawa
    • Hisamitsu Miyaaki
    • Satoshi Miuma
    • Yasuhide Motoyoshi
    • Mio Yamashima
    • Shinobu Yamamichi
    • Makiko Koike
    • Yusuke Nakano
    • Tetsurou Honda
    • Hiroyuki Yajima
    • Osamu Miyazaki
    • Yasutaka Kuribayashi
    • Tomonari Ikeda
    • Naota Taura
    • Kazuhiko Nakao
  • View Affiliations

  • Published online on: November 24, 2021     https://doi.org/10.3892/br.2021.1489
  • Article Number: 6
  • Copyright: © Okamura et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Hepatitis B virus (HBV) infection is associated with the risk of osteoporosis and bone mineral density (BMD) loss. Tenofovir alafenamide (TAF) is associated with a slightly lower degree of BMD loss compared with tenofovir disoproxil, without loss of the excellent anti‑HBV effects. The aim of the present study was to verify the effect of bone metabolism in patients with HBV treated with TAF. A total of 87 patients were treated with TAF. Of these, 32 patients were treatment naïve, and 55 patients were treated with entecavir (ETV) for at least 1 year, after which ETV was switched to TAF. At the start of TAF and after 1 year, BMD in the lumbar and neck of the femur, tartrate‑resistant acid phosphatase isoform 5b (TRACP‑5b) levels as a marker of bone metabolism and serum inorganic phosphorus (P) were compared to estimate bone metabolism. Serum creatinine (Cr), cystatin C, urine protein and β2 microglobulin levels were evaluated to estimate kidney function. Treatment with TAF for 1 year decreased TRACP‑5b levels, particularly in patients with bone disease, except for a minimal significant change (MSC; decrease of 12.4%) in TRACP‑5b levels. The change in rate of TRACP‑5b levels were positively associated with changes in P, Cr‑estimated glomerular filtration rate and TRACP‑5b levels at the start of TAF. Logistic regression analysis showed that increased BMD in the lumbar region contributed to the switch from ETV to TAF. TAF induced a decrease in TRACP‑5b levels in patients with HBV. Bone disease was a contributing factor for MSC. Since TRACP‑5b can be used as a marker of bone metabolism and fractures, TAF may exhibit potential in preventing fractures in patients with HBV.

Related Articles

Journal Cover

January-2022
Volume 16 Issue 1

Print ISSN: 2049-9434
Online ISSN:2049-9442

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Okamura T, Ichikawa T, Miyaaki H, Miuma S, Motoyoshi Y, Yamashima M, Yamamichi S, Koike M, Nakano Y, Honda T, Honda T, et al: Change in tartrate‑resistant acid phosphatase isoform 5b levels, a marker of bone metabolism, in patients with chronic hepatitis B treated with tenofovir alafenamide. Biomed Rep 16: 6, 2022
APA
Okamura, T., Ichikawa, T., Miyaaki, H., Miuma, S., Motoyoshi, Y., Yamashima, M. ... Nakao, K. (2022). Change in tartrate‑resistant acid phosphatase isoform 5b levels, a marker of bone metabolism, in patients with chronic hepatitis B treated with tenofovir alafenamide. Biomedical Reports, 16, 6. https://doi.org/10.3892/br.2021.1489
MLA
Okamura, T., Ichikawa, T., Miyaaki, H., Miuma, S., Motoyoshi, Y., Yamashima, M., Yamamichi, S., Koike, M., Nakano, Y., Honda, T., Yajima, H., Miyazaki, O., Kuribayashi, Y., Ikeda, T., Taura, N., Nakao, K."Change in tartrate‑resistant acid phosphatase isoform 5b levels, a marker of bone metabolism, in patients with chronic hepatitis B treated with tenofovir alafenamide". Biomedical Reports 16.1 (2022): 6.
Chicago
Okamura, T., Ichikawa, T., Miyaaki, H., Miuma, S., Motoyoshi, Y., Yamashima, M., Yamamichi, S., Koike, M., Nakano, Y., Honda, T., Yajima, H., Miyazaki, O., Kuribayashi, Y., Ikeda, T., Taura, N., Nakao, K."Change in tartrate‑resistant acid phosphatase isoform 5b levels, a marker of bone metabolism, in patients with chronic hepatitis B treated with tenofovir alafenamide". Biomedical Reports 16, no. 1 (2022): 6. https://doi.org/10.3892/br.2021.1489